| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-04-29 | Sanofi (France) Oxford Biomedica (UK) | StarGen™, UshStat®, EncorStat®, RetinoStat® | Stargardt's disease- Usher syndrome type 1B - corneal graft rejection - wet age-related macular degeneration | licensing |
Ophtalmalogical diseases - Genetic diseases - Rare diseases | Licensing agreement |
| 2014-04-29 | MorphoSys (Germany) Temple University (USA - PA) | therapeutic antibodies - Ylanthia® technology | R&D |
Technology - Services | Establishment of a new subsidiary in the EU | |
| 2014-04-29 | AAVLife (France) RegenX Biosciences (USA - MD) | NAV rAAVrh10 vector | Friedreich's Ataxia | development commercialisation |
Rare diseases - Neurodegenerative diseases | Development agreement |
| 2014-04-28 | Transgene (France) Novartis (Switzerland) | TG4010 (MVA-MUC1-IL2) | advanced non-small cell lung cancer | Cancer - Oncology | Refusal of an option | |
| 2014-04-27 | Teva Pharmaceuticals (Israel) Takeda Pharmaceutical (Japan) | rasagiline | Parkinson's disease | commercialisation | Neurodegenerative diseases - CNS diseases | Commercialisation agreement |
| 2014-04-25 | LEO Pharma (Denmark) Fidelta (Croatia - a Galapagos company Belgium) | drug discovery services | Dermatological diseases | R&D services |
Dermatological diseases | Services contract |
| 2014-04-25 | Fresenius Kabi (Germany) Sistema JSFC (Russia) Zenitco Finance Management (Russia) | joint-venture |
Joint-venture agreement | |||
| 2014-04-24 | VolitionRX (Singapore) Rheinische Friedrich-Wilhelms-Universität Bonn (Bonn University) (Germany) | NuQ™ assays | major organ and hematological cancers | collaboration |
Diagnostic - Cancer - Oncology | Clinical research agreement |
| 2014-04-24 | Epigenomics (Germany - USA) BioChain (USA - CA - China) | septin9 | colorectal cancer | licensing |
Diagnostic - Cancer - Oncology | Licensing agreement |
| 2014-04-24 | Celgene (USA - NJ) Nogra Pharma (Ireland) | GED-0301 (antisense DNA oligonucleotide targeting Smad7 mRNA) | Crohn's Disease | licensing development commercialisation |
Autoimmune diseases – Inflammatory diseases - Digestive diseases | Licensing agreement |
| 2014-04-24 | Cell Therapy Catapult (UK) Athersys (USA - OH) | MultiStem® | collaboration |
Regenerative medicine | Collaboration agreement | |
| 2014-04-24 | Boehringer Ingelheim (Germany) Hydra Biosciences (USA - MA) | small-molecule TRPC4/5 inhibitors | R&D |
CNS diseases | R&D agreement | |
| 2014-04-24 | ALK Abello (Denmark) Eddingpharm (China) | Soluprick® SQ Alutard SQ® | house dust mite allergy | collaboration |
Allergic diseases - Immunological diseases | Collaboration agreement |
| 2014-04-23 | immatics biotechnologies (Germany) Cancer Research UK (UK) Cancer Research Technology (UK) | IMA950 | glioblastoma | licensing |
Cancer - Oncology | Licensing agreement |
| 2014-04-23 | ONcoDNA (Belgium) Breast International Group (BIG) | testing and analysis of primary and metastatic tumours and blood samples for AURORA programme | breast cancer | services |
Diagnostic - Cancer - Oncology | Services contract |
| 2014-04-22 | Swedish Orphan Biovitrum - SOBI (Sweden) - Affibody (Sweden) | interleukin-1 (IL-1) | inflammatory diseases where Interleukin-1 (IL-1) is implicated | R&D licensing |
Inflammatory diseases | Exercise of an option agreement |
| 2014-04-22 | Sentinel Oncology (UK) Oncothyreon (USA - WA) | Checkpoint Kinase 1 (Chk1) programme | collaboration development |
Cancer - Oncology | Collaboration agreement | |
| 2014-04-22 | MDxHealth (Belgium) Galaxy Health Network (USA -TX) | ConfirmMDx® for Prostate Cancer | prostate cancer | Diagnostic - Cancer - Oncology | Distribution agreement | |
| 2014-04-22 | HemoShear (USA - VA) Medivir (Sweden) | undisclosed | R&D |
undisclosed | R&D agreement | |
| 2014-04-22 | Enterome Bioscience (France) | nomination | Nomination |
